Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SPRB
STRONG SELLSpruce Biosciences, Inc. · Healthcare · United States · $119M · Avg Vol: $3M/d
5
StockRankGet insider-trade alerts
Q
21
V
31
M
20
P/E (TTM)
—
ROE
-148.8%
D/E
0.2x
Dividend %
—
Loading 1Y...
PRICE (1Y)-19.1%
SMA 50SMA 200
Close
$41.99
RSI (14)
25.2
52W High
$838.13
From 52W High
0.1%
SCORE BREAKDOWN
Quality
21
ROIC
-84.9%7.7
ROE
-148.8%5.8
GP/Assets
-19.5%5.0
Op. Margin
0.0%41.3
FCF/Assets
-25.2%14.2
Piotroski
239.0
Int. Cover
-50.0x6.3
D/E Ratio
0.21x49.4
Current Ratio
4.67x68.5
Value
31
P/E (TTM)
—N/A
EV/EBITDA
-2.8x25.0
P/FCF
—N/A
P/B
1.7x66.5
P/S
—N/A
Div Yield
—N/A
Momentum
20
52W High %
5%0.3
RS 6M
-56%10.9
SMA 50/200
0.66x6.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+121%77.7
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$119M
P/E (Forward)
5.8x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SPRB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SPRB | Spruce Biosciences, Inc.(you) | $119M | 5 | STRONG SELL |
| GUTS | Fractyl Health, Inc. | $123M | 5 | STRONG SELL |
| RANI | Rani Therapeutics Holdings, Inc. | $117M | 2 | STRONG SELL |
| ONCY | Oncolytics Biotech Inc. | $97M | 5 | STRONG SELL |
| GNLX | Genelux Corporation | $130M | 7 | STRONG SELL |
| 2592.HK | Cloudbreak Pharma Inc. | $110M | 1 | STRONG SELL |
| PLYX | Polaryx Therapeutics, Inc. | $102M | 6 | STRONG SELL |
| ALDX | Aldeyra Therapeutics, Inc. | $92M | 4 | STRONG SELL |
| ALEC | Alector, Inc. | $164M | 5 | STRONG SELL |
| PEPG | PepGen Inc. | $133M | 9 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%